Intrexon (XON) has made a small yet strategic acquisition in buying GenVec (GNVC); with the purchase, XON gets AdenoVerse, a platform of adenovirus vectors for delivering drugs and vaccines that dovetails nicely with its existing suite of gene therapy technologies, suggests John McCamant, editor of The Medical Technology Stock Letter.
The ability to increase the payloads of viral vectors....More>>>
24/7 Wall St. has put together a preview of some of the major companies reporting their quarterly results this week. We are currently in between earnings seasons, but there are still a few major companies reporting in the meantime. We have included the consensus earnings estimates from Thomson Reuters and the stock price and trading history, as well as added some additional color on each.
Europes main stock benchmark finished with a small gain on Monday, with rises for commodities-related companies, French telecom SFR Group SA and Swiss software maker Temenos Group AG helping to lead the gauge higher.
The Stoxx Europe 600 ....More>>>
Opiates are incredibly potent pain relievers forpatients with severe traumatic pain or dealing with end-of-life care, but they are also being increasingly abused. Robert Brooke, the CEO of small cap Vitality Biopharma, Inc. (OTCQB: VBIO), which is dedicated to the development of cannabinoid prodrug pharmaceuticals and to unlocking the power of cannabinoids for the treatment of serious neurological....More>>>